Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
QuintilesIMS
McKinsey
Boehringer Ingelheim
US Army
Citi
Federal Trade Commission
Medtronic
Queensland Health

Generated: April 23, 2018

DrugPatentWatch Database Preview

STRATTERA Drug Profile

« Back to Dashboard

When do Strattera patents expire, and what generic alternatives are available?

Strattera is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in STRATTERA is atomoxetine hydrochloride. There are fourteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the atomoxetine hydrochloride profile page.
Drug patent expirations by year for STRATTERA
Pharmacology for STRATTERA
Medical Subject Heading (MeSH) Categories for STRATTERA
Synonyms for STRATTERA
(-)-N-methyl-3-phenyl-3-(o-tolyloxy)-propylamine hydrochloride
(-)-N-Methyl-3-phenyl-3-(o-tolyloxy)propylamine hydrochloride
(3R)-N-methyl-3-(2-methylphenoxy)-3-phenyl-propan-1-amine hydrochloride
(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine hydrochloride
(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine;hydrochloride
(R)-(-)-N-methyl-3-(2-methylphenoxy)-3-phenylpropylamine hydrochloride
(R)-(-)-Tomoxetine hydrochloride
(R)-ATOMOXETINE HYDROCHLORIDE
(R)-N-Methyl-?-(2-methylphenoxy)-benzenepropanamine hydrochloride
(R)-N-Methyl-3-(2-methylphenoxy)-3-phenylpropylamine Hydrochloride
(R)-N-METHYL-3-PHENYL-3-(O-TOLYLOXY)PROPAN-1-AMINE HCL
(R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine hydrochloride
(R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-aminehydrochloride
(R)-N-Methyl-gamma-(2-methyl-phenoxy)benzenepropanamine hydrochloride
(r)-n-methyl-gamma-(2-methylphenoxy)-benzenepropanamine hydrochloride
(R)-N-METHYL-GAMMA-(2-METHYLPHENOXY)BENZENEPROPANAMINE HYDROCHLORIDE
(R)-Tomoxetine hydrochloride
(R)-Tomoxetine hydrochloride, solid
248T597
57WVB6I2W0
82248-59-7
83015-26-3 (Parent)
AB0014234
AB25136
AC1L1HTF
AK-72912
AKOS015920150
AM20060733
Ambap82248-59-7
AN-11139
API0001557
AT-20429
Atomexine Hydrochloride, pharmaceutical secondary standard
ATOMOXETIN HCL
Atomoxetine (hydrochloride)
Atomoxetine for impurity A identification, European Pharmacopoeia (EP) Reference Standard
Atomoxetine HCL
Atomoxetine hydrochloride
Atomoxetine hydrochloride (JAN/USP)
Atomoxetine hydrochloride [USAN]
Atomoxetine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Atomoxetine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Atomoxetine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Atomoxetine hydrochloride, United States Pharmacopeia (USP) Reference Standard
BENZENEPROPANAMINE, N-METHYL-G-(2-METHYLPHENOXY)-, HYDROCHLORIDE (1:1), (GR)-
Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, hydrochloride, (-)-
BR-72912
C17H21NO.HCl
CAS-82248-59-7
CCG-100874
CHEBI:331697
CHEMBL1702
CPD000469177
CS-1085
D02574
DSSTox_CID_24266
DSSTox_GSID_44266
DSSTox_RID_80136
DTXSID2044266
F0001-2408
FT-0655350
HY-17385
K464
KS-1223
LS-177676
LUCXVPAZUDVVBT-UNTBIKODSA-N
LY 139603
LY 139603 HYDROCHLORIDE
LY-135252
LY-139602 [(+)-isomer]
LY-139603
LY139603
M-1314
METHYL-((R)-3-PHENYL-3-O-TOLYLOXY-PROPYL)-AMINE HYDROCHLORIDE
MFCD06410992
MLS001401377
MLS002153176
MolPort-003-983-468
NC00124
NCGC00016056-02
NCGC00025345-02
OR348051
s3175
SAM001246626
SC-17967
SCHEMBL122111
SMR000469177
ST24020766
Strattera (TN)
Tomoxetine
Tomoxetine HCl
TOMOXETINE HYDROCHLORIDE
tomoxetine hydrochloride, (-)-isomer
Tox21_110292
Tox21_110292_1
UNII-57WVB6I2W0

US Patents and Regulatory Information for STRATTERA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-007 Feb 14, 2005 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-004 Nov 26, 2002 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-008 Feb 14, 2005 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for STRATTERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-007 Feb 14, 2005 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-003 Nov 26, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-004 Nov 26, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly STRATTERA atomoxetine hydrochloride CAPSULE;ORAL 021411-001 Nov 26, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for STRATTERA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg ➤ Subscribe 2007-05-29

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
UBS
Medtronic
Colorcon
Chinese Patent Office
Boehringer Ingelheim
Chubb
US Department of Justice
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.